Bridgewater, NJ, June 26, 2025 - Amneal Pharmaceuticals, Inc. today published its 2024 Responsible Business Report, highlighting progress in expanding access to medicines, advancing environmental sustainability, supporting workforce development and upholding ethical business practices.
Now in its fifth year, the report reflects Amneal’s ongoing commitment to making healthcare more equitable, sustainable and resilient.
This year, Amneal introduced a new environmental, social and governance (ESG) framework to bring greater structure and focus to its efforts. Built around three strategic pillars — Our Societal Impact, Our Environmental Impact, and Our People & Practices — the framework aligns with global standards and helps more deeply integrate ESG into Amneal’s core business strategies. This framework will also guide future ESG disclosures and communications.
Highlights from this year’s report include:
· Expanding Access in America: In 2024, Amneal filled over 162 million prescriptions in the U.S.,[1] delivering an estimated $18.25 billion in patient savings.[2] The company launched 22 new generic products, expanded its biosimilars pipeline and introduced CREXONT® for Parkinson’s disease. Amneal also helped mitigate national drug shortages by producing over 10 critical injectable medicines for U.S. hospitals and health systems. In addition, Amneal donated more than 83,000 units of Naloxone HCl nasal spray to nonprofit and harm-reduction organizations.
· Reducing Environmental Impact: One of Amneal’s India-based manufacturing facilities transitioned from coal to cleaner-burning biomass, eliminating approximately 1,600 tons of CO₂ emissions annually. Amneal also disclosed full-year data on greenhouse gas emissions, energy, water and waste data across global operations, and supported the planting of over 10,000 trees through a partnership with One Tree Planted.
· Investing in People: Amneal launched My Amneal Career, a global talent development framework designed to give employees greater visibility into career paths and skills-building opportunities. Global employee engagement rose to 88%, 11 points higher than the pharmaceutical industry benchmark, and reflects employees feeling valued, excited by their work and motivated to contribute more than expected. Amneal also avoided U.S. employee healthcare cost increases and was recognized in India for its efforts to advance gender inclusion in the workplace.
The 2024 report was developed with reference to the Global Reporting Initiative (GRI), the SASB Biotechnology & Pharmaceuticals Standard, and includes alignment with several UN Sustainable Development Goals.
To explore the full 2024 Responsible Business Report, visit amneal.com/responsibility.
[1] Source: IQVIA, Nation Prescription Audit, December 2024, Note: Total Scripts filled in 2024